Analyst Rating Update on Alder BioPharmaceuticals (ALDR)

Alder BioPharmaceuticals (NASDAQ:ALDR) has an average broker rating of 1, which is interpreted as a Strong Buy, as rated by 4 equity analysts. Nonetheless, 4 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Ranking by Zacks Investment Research for Coach Inc is 4, which is also a Sell.

Alder BioPharmaceuticals (NASDAQ:ALDR) : The consensus price target for Alder BioPharmaceuticals (NASDAQ:ALDR) is $49 for the short term with a standard deviation of $10.58. The most optimist securities analyst among the 3 who monitor the stock believes that the stock can reach $61, however, the pessimist price target for the company is $41.

For this week, the average consensus of the company shares are rated as a Strong Buy.

Alder BioPharmaceuticals (NASDAQ:ALDR): stock turned positive on Tuesday. Though the stock opened at $23.22, the bulls momentum made the stock top out at $24.27 level for the day. The stock recorded a low of $23.22 and closed the trading day at $24.1, in the green by 5.15%. The total traded volume for the day was 701,491. The stock had closed at $22.92 in the previous days trading.

In an insider trading activity, The officer (Chief Business Officer), of Alder Biopharmaceuticals Inc, Litton Mark James had unloaded 6,000 shares at $29.25 per share in a transaction on June 13, 2016. The total value of transaction was $175,500. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.

Alder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response. The Companys pipeline includes ALD403, Clazakizumab and ALD1613. ALD403 is the Companys monoclonal antibody targeted to calcitonin gene-related peptide (CGRP) for migraine prevention. Clazakizumab is a monoclonal antibody that inhibits the pro-inflammatory cytokine interleukin-6 (IL-6), and is in development for both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). ALD1613 is a monoclonal antibody that inhibits Adrenocorticotropic Hormone (ACTH), and is being developed for the treatment of Cushings disease.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.